2021年8月19日 · What is LL-37 Antimicrobial Peptide? LL-37 is a 37-amino-acid peptide that is directly derived from the C-terminal of a larger protein in your body known as a cathelicidin, which simply refers to an antimicrobial peptide that kills foreign …

LL-37 is able to kill bacteria through direct antibacterial activities, as well as through immunomodulation. Like other AMPs, the primary mechanism of action is membrane disruption. The net positive charge of +6 allows for LL-37 to bind to the negatively charged membrane of …

Cathelicidin antimicrobial peptide (CAMP) is an antimicrobial peptide encoded in the human by the CAMP gene. [1] . The active form is LL-37. In humans, CAMP encodes the peptide precursor CAP-18 (18 kDa), which is processed by proteinase 3 -mediated extracellular cleavage into the active form LL-37. [2][1]

LL-37, expressed on the surface of neutrophils is recognized by anti-LL-37 autoantibodies, which promotes NETosis, generating a source of additional LL-37 DNA complexes. However, LL-37 has strong anti-inflammatory effects such as neutralization of TLR4 activation by LPS, downmodulation of inflammatory cytokine responses and preventing invasion ...

LL-37 plays an important role in the first line of defense against infection and systemic invasion of pathogens at sites of inflammation and wound. It is cytotoxic to both bacterial and normal eukaryotic cells and is significantly resistant to proteolytic degradation in solution.

2024年3月8日 · In this review article, we aim to develop integrative, mechanistic insight into LL37 and its derived peptides, based on the known biophysical, structural, and functional studies in recent years.

2020年8月4日 · LL-37 17–29 correspondingly forms wide, ribbon-like, thermostable fibrils in solution, which co-localize with bacterial cells. Structure-guided mutagenesis analyses supports the role of...

LL-37, the only human cathelicidin-derived antimicrobial peptide, has long been a popular research subject because of its special abilities and vast applications. In the past 15 years, hundreds of papers have been published with LL-37 being their primary focus.

2025年1月1日 · Offering new strategies for treating chronic infections, LL-37 disrupts biofilms, particularly in antibiotic-resistant bacteria. Displaying both anti- and pro-cancerous effects, LL-37 plays a complex role, impacting immune responses and signalling pathways.

LL-37 (CAS number: 154947-66-7), also known as hCAP18, is the C-terminal part of the only human cathelicidin identified to date called human cationic antimicrobial protein (hCAP). LL-37 exhibits a variety of immunomodulatory functions such as bactericidal action, chemotaxis, activation of chemokine